Biological Markers for Post-Traumatic Stress Disorder

Last updated: February 4, 2024
Sponsor: Assaf-Harofeh Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Post-traumatic Stress Disorders

Treatment

Autonomic nervous system monitors

Clinician Administered Dissociative States Scale

A diary will be used for seven consecutive nights

Clinical Study ID

NCT05213858
178-21
  • Ages 20-60
  • Male
  • Accepts Healthy Volunteers

Study Summary

The current study aims to evaluate the sensitivity and specificity of a combination of various objective biomarkers for the diagnosis of PTSD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. The willingness and ability to read, understand and sign an informed consent form.
  2. Age 20-60 years.
  3. A history of more than 2 years of combat service, and of at least one potentiallylife-threatening combat experience.
  4. One year or more after the last combat experience.

Exclusion

Exclusion Criteria:

  1. Inability to attend scheduled clinic visits or comply with the study protocol
  2. A history of traumatic brain injury or any other known brain pathology.
  3. Substance use, except for prescribed cannabis, if it can be withheld for at least 24hours prior to the study evaluation.
  4. A current psychiatric disorder other than PTSD.
  5. The inability to perform an awake brain MRI.

Study Design

Total Participants: 300
Treatment Group(s): 12
Primary Treatment: Autonomic nervous system monitors
Phase:
Study Start date:
January 01, 2022
Estimated Completion Date:
January 01, 2026

Study Description

PTSD affects a major fraction of military combatants and is also very common in the general population. Like other psychiatric conditions, the diagnosis of PTSD is currently based on an interview and questionnaires. However, the validity of these tools is limited since it depends on the evaluator's skills, and on patient compliance and mental status; and may be prone to exaggeration or minimization of symptoms. This prompts an urgent need for evaluation that will combine biomarkers for objective diagnosis, and follow up of individuals with PTSD.

Knowledge has grown in recent years regarding the biologic pathophysiological cascade responsible for the development of a "non-healing wound in the brain" that characterizes PTSD. Shortly after the traumatic experience, fundamental changes in autonomic nervous and endocrine activity are evident, together with changes in brain function; these can become chronic in those with long-standing unremitting PTSD. Several studies indicate good correlations of the diagnosis and severity of PTSD, with objective biological measures such as heart rate variability (HRV), brain connectivity and endocrine activity. However, the currently available data on these biological variables are still not sufficient to be used for diagnosis of PTSD.

The aim of the current study is to characterize the biological fingerprint of PTSD, by using a combination of biological measures, for an objective diagnosis.

Connect with a study center

  • Assaf-Harofeh Medical Center

    Ramla, 70300
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.